Patient baseline characteristics
. | Control . | ACD . | IDA . | HS . |
|---|---|---|---|---|
| No. patients | 27 | 37 | 10 | 10 |
| Age, y | 52.0 ± 19.0 | 67.0 ± 20.0* | 43.1 ± 19.0† | |
| Sex, F/M | 9/18 | 16/19 | 8/2ठ| 5/5 |
| Hb level, g/L | 151 ± 11 | 107 ± 14‡ | 100 ± 17‡ | 102 ± 13‡ |
| MCH level, pg | 31.0 ± 1.5 | 29.3 ± 2.5* | 23.5 ± 5.3‡ | 28.7 ± 1.5‡ |
| MCV, fL | 92.1 ± 3.51 | 87.9 ± 7.2* | 78.4 ± 8.3‡ | 83.0 ± 7.7‡ |
| Fe level, μM | 19.4 ± 7.7 | 5.5 ± 2.4‡ | 7.1 ± 4.0‡ | 19.6 ± 8.0§ |
| Ferritin level, μg/L | 113.5 ± 86.9 | 589.0 ± 647.2‡ | 12.9 ± 10.0‡§ | 304.4 ± 199.0‡§ |
| Transferrin level, g/L | 2.78 ± 0.38 | 1.6 ± 0.5‡ | 3.94 ± 0.54‡† | 2.78 ± 0.39† |
| TfS, % | 27.9 ± 9.8 | 13.6 ± 5.7‡ | 9.3 ± 7.7‡ | 40.4 ± 17.9† |
| Folic acid level, μg/L | 9.2 ± 2.7 | 9.6 ± 13.7 | 9.9 ± 6.3 | ND |
| Cobalamine level, ng/L | 473.0 ± 214.0 | 531.0 ± 420.0 | 343.0 ± 136.0 | ND |
| Epo level, IU/L | 10.4 ± 19.4 | 16.6 ± 10.6 | 37.7 ± 36.3*§ | 66.1 ± 36.2‡† |
. | Control . | ACD . | IDA . | HS . |
|---|---|---|---|---|
| No. patients | 27 | 37 | 10 | 10 |
| Age, y | 52.0 ± 19.0 | 67.0 ± 20.0* | 43.1 ± 19.0† | |
| Sex, F/M | 9/18 | 16/19 | 8/2ठ| 5/5 |
| Hb level, g/L | 151 ± 11 | 107 ± 14‡ | 100 ± 17‡ | 102 ± 13‡ |
| MCH level, pg | 31.0 ± 1.5 | 29.3 ± 2.5* | 23.5 ± 5.3‡ | 28.7 ± 1.5‡ |
| MCV, fL | 92.1 ± 3.51 | 87.9 ± 7.2* | 78.4 ± 8.3‡ | 83.0 ± 7.7‡ |
| Fe level, μM | 19.4 ± 7.7 | 5.5 ± 2.4‡ | 7.1 ± 4.0‡ | 19.6 ± 8.0§ |
| Ferritin level, μg/L | 113.5 ± 86.9 | 589.0 ± 647.2‡ | 12.9 ± 10.0‡§ | 304.4 ± 199.0‡§ |
| Transferrin level, g/L | 2.78 ± 0.38 | 1.6 ± 0.5‡ | 3.94 ± 0.54‡† | 2.78 ± 0.39† |
| TfS, % | 27.9 ± 9.8 | 13.6 ± 5.7‡ | 9.3 ± 7.7‡ | 40.4 ± 17.9† |
| Folic acid level, μg/L | 9.2 ± 2.7 | 9.6 ± 13.7 | 9.9 ± 6.3 | ND |
| Cobalamine level, ng/L | 473.0 ± 214.0 | 531.0 ± 420.0 | 343.0 ± 136.0 | ND |
| Epo level, IU/L | 10.4 ± 19.4 | 16.6 ± 10.6 | 37.7 ± 36.3*§ | 66.1 ± 36.2‡† |
Data are shown as means ± SD in each group.
Hb indicates hemoglobin; MCH, mean corpuscular Hb; MCV, mean corpuscular volume; TfS, transferrin saturation; ND, not done; and Epo, erythropoietin.
P < .05 when comparing control subjects with ACD, IDA, HS.
P < .001 when comparing ACD with IDA or HS by means of Student t test.
P < .001 when comparing control subjects with ACD, IDA, or HS.
P < .05 when comparing ACD with IDA or HS by means of Student t test.